Vivek GaripalliAn Optimistic Viewpoint on Government Entitlement SpendingIn recent years, particularly after the pandemic, there has been a lot of doom and gloom amongst economists and professional investors…Aug 15Aug 15
Vivek GaripalliA Bipartisan Approach to Medicare for AllThis post represents my personal viewpoint only and in no way is meant to represent the viewpoint(s) of any companies I’m invested in…Jul 17Jul 17
Vivek GaripalliEndorsing Progress: Advocating for CMS’s New Agent/Broker Rules in Medicare Advantage(TLDR: I absolutely love the new proposed rules :-) — and believe they can go even further)Dec 1, 2023Dec 1, 2023
Vivek GaripalliReviving Urban Spaces: The Promise of Converting Commercial Properties to Residential UseThe evolution of urban spaces has seen numerous highs and lows. The aftermath of economic downturns, technological shifts, and migration…Nov 8, 2023Nov 8, 2023
Vivek GaripalliThe No UPCODE Act: A Step Toward True Long-Term Bipartisan Support for Medicare AdvantageThe Medicare Advantage (MA) industry is at a crossroads. While the program has enjoyed bipartisan support in the past, that support has…May 1, 2023May 1, 2023
Vivek Garipalli2024 CMS Rate Advance Notice: Big Win for Medicare Advantage BeneficiariesTHE ENTIRETY OF THIS POST REPRESENTS MY PERSONAL OPINION, AND IS NOT WRITTEN ON BEHALF OF ANY ORGANIZATION.Feb 21, 2023Feb 21, 2023
Vivek GaripalliA Win for CMS and Taxpayers, but Medicare Advantage Plans are in an UproarTHE ENTIRETY OF THIS POST REPRESENTS MY PERSONAL OPINION, AND IS NOT WRITTEN ON BEHALF OF ANY ORGANIZATION.Feb 6, 20231Feb 6, 20231
Vivek GaripalliClover — 2023 and BeyondI’m beyond excited for Clover’s future, and especially with this being the first week with Andrew Toy as CEO. I look forward to everyone…Jan 5, 2023Jan 5, 2023
Vivek GaripalliClover — My Long-term View(from the Nov 7, 2022 Q3 Clover earnings call)Nov 9, 20222Nov 9, 20222
Vivek GaripalliCharacter Biosciences (formerly Clover Therapeutics)I am beyond proud to see Character Biosciences (formerly Clover Therapeutics) land a significant milestone round of $18mm, with Clover…May 17, 2022May 17, 2022